SBIR Phase I: A Novel Extended Delivery Dual-action Platform for Peptide-based Anti-fibrotics

SBIR 第一阶段：基于肽的抗纤维化的新型延长递送双作用平台

• 批准号: 1345892
• 负责人: Prakash Narayan
• 金额: $ 14.98万
• 依托单位: Angion Biomedica Corp
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-01-01 至 2014-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1345892&HistoricalAwards=false
• 关键词: SBIR; Phase; Novel; Extended; Delivery

This Small Business Innovation Research (SBIR) Phase I project seeks to develop a new drug-delivery microscaffold that can help millions of patients suffering from chronic kidney, liver or lung disease. These diseases are characterized by chronic inflammation of the organ, stiffening or hardening of the organ and a gradual decline in organ function. The proposed microscaffold brings together on one single platform two drugs with very different actions. One drug is aspirin that reduces inflammation and the other drug is Relaxin which can soften hardened tissue and preserve tissue function. Unfortunately, Relaxin cannot be taken orally and is therefore not being used for these indications. This microscaffold, to be implanted under the skin, is designed to release these drugs continuously over several days or weeks. This Phase I program seeks to demonstrate the feasibility of such a concept in cell-based studies by demonstrating that this microscaffold releases both aspirin and Relaxin and that these two drugs retain their activities.The broader impact/commercial potential of this project is significant. These chronic diseases are currently without cure. In fact, chronic kidney disease, cirrhosis and idiopathic pulmonary fibrosis all necessitate organ transplant. In addition to their attendant morbidity and mortality, these diseases cost this country billions of dollars in health care expenses and lost wages. The potential healthcare impact of this highly innovative technology is exceptionally broad. Sustained-release microscaffolds will enable less frequent dosing and translate to better patient compliance. In fact, similar to antibody-based therapies, this extended-release scaffold might necessitate administration only once monthly or even less frequently. By encapsulating a variety of highly potent drugs from insulin to growth factors, custom platforms can be designed to treat a host of indications such as diabetes, keloid scars and tissue fibrosis.

这项小型企业创新研究（SBIR）I期项目旨在开发一种新的药物显微镜，该显微镜可以帮助数百万患者患有慢性肾脏，肝脏或肺部病的患者。这些疾病的特征是器官慢性炎症，器官僵硬或硬化的器官功能逐渐下降。拟议的显微镜在一个单一平台上汇集了两种具有截然不同作用的药物。一种药物是阿司匹林，可减少炎症，另一种药物是松弛蛋白，可以软化硬化组织并保留组织功能。不幸的是，放松素不能口服，因此不用于这些适应症。该显微镜将植入皮肤下，旨在在几天或几周内连续释放这些药物。该阶段I计划旨在通过证明该显微镜释放阿司匹林和松弛素来证明这种概念在基于细胞的研究中的可行性，并且这两种药物保留其活动。该项目的更广泛的影响/商业潜力很重要。这些慢性疾病目前无法治愈。实际上，慢性肾脏疾病，肝硬化和特发性肺纤维化都需要器官移植。除了伴随的发病率和死亡率外，这些疾病还花费了这一国数十亿美元的医疗费用和损失的工资。这项高度创新技术的潜在医疗保健影响非常广泛。持续释放的显微镜将使频繁的给药量较低，并转化为更好的患者依从性。实际上，与基于抗体的疗法类似，这种扩展的释放脚手架可能只需要每月一次甚至频繁一次。通过封装从胰岛素到生长因素的各种高度有效的药物，可以设计定制平台来治疗许多适应症，例如糖尿病，酮疤痕和组织纤维化。